Form 4 for PCVX Vaxcyte, Inc.
Accepted 2023-03-03 00:00:00 ET · period of report 2023-03-01 · accession 0001209191-23-015724 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-03 | 2023-03-01 | PCVX | Eydelman Mikhail | SVP, Gen Counsel, Corp Sec | A - Grant | $0.00 | +13.8K | 21.8K | +171% | $0 |
| D | 2023-03-03 | 2023-03-01 | PCVX | Eydelman Mikhail | SVP, Gen Counsel, Corp Sec | A - Grant | $0.00 | +82.5K | 82.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-01 | A | A | 13,750 | $0.00 | 21,782 | D | — | — | (F1) Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2023 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| 2 | Derivative | Stock Option (right to buy) | 2023-03-01 | A | A | 82,500 | $0.00 | 82,500 | D | $41.67 · — to 2033-03-01 | 82,500 Common Stock | (F2) 1/48 of shares subject to the option vest on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |